# Endovascular Engineering ENGULF Study

Study · id `cardio:ct-nct05597891` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05597891](<https://clinicaltrials.gov/study/NCT05597891>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05597891

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 177 participants.

## Technical summary

Registry record NCT05597891. Allocation not applicable; no masking; primary purpose treatment. Start 2023-01-12 (actual); primary completion 2026-03-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 177 participants (enrolled count; ClinicalTrials.gov record NCT05597891, source copy `cardio:ctgov-nct05597891-2026-04-14`, retrieved 2026-10-31)
- Started: 2023-01-12 (actual) (ClinicalTrials.gov record NCT05597891, source copy `cardio:ctgov-nct05597891-2026-04-14`, retrieved 2026-10-31)
- Primary completion: 2026-03-02 (actual) (ClinicalTrials.gov record NCT05597891, source copy `cardio:ctgov-nct05597891-2026-04-14`, retrieved 2026-10-31)
- Completion: 2026-03-30 (actual) (ClinicalTrials.gov record NCT05597891, source copy `cardio:ctgov-nct05597891-2026-04-14`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT05597891, source copy `cardio:ctgov-nct05597891-2026-04-14`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05597891-2026-04-14`, retrieved 2026-10-31)

## The registry's words

- Brief title: Endovascular Engineering ENGULF Study
- Acronym: ENGULF
- Condition: Pulmonary Embolism
- Intervention (Device): Hēlo PE Thombectomy System
- Lead sponsor: Endovascular Engineering
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary embolism (`cardio:pulmonary-embolism`)

## Provenance

Content hash: 171fecace0f359cfe264c2f1d3a76e12b2977add2c398696b2778b2602801ca4
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
